Solace Health completes a new funding round, valued at $1 billion - Bloomberg

LootboxPhobia · 2026-02-11T22:12:35+00:00

Health startup Solace Health reaches a $1 billion valuation after raising $130 million, aiming to help patients navigate the U.S. healthcare system. The company was founded by Jeremy Gurewitz and has over 2,000 nurses serving as patient advocates. It plans to use the new funding for marketing and hiring.

LootboxPhobia

2026-02-11 22:12:35

Abstract generation in progress

Investing.com – According to Bloomberg on Tuesday, health advocacy startup Solace Health has reached a $1 billion valuation after securing $130 million in new funding led by venture capital firm IVP.

The startup, which helps patients navigate the U.S. healthcare system, also received investments from Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures.

Founded in 2022 by CEO Jeremy Gurewitz, Solace Health was inspired by his mother’s experience of passing away from pancreatic cancer. The company offers services to assist patients in scheduling appointments, understanding treatment plans, and interpreting medical bills. Gurewitz noted that despite his mother being a doctor herself, she still faced difficulties navigating the healthcare system during her cancer treatment.

The platform currently has over 2,000 patient advocates, all of whom are registered nurses. Solace’s technology handles Medicare billing and provides tools, including an internal electronic medical record system that connects to patients’ health histories. The company generates revenue by taking a variable share of Medicare reimbursements from advocates using its platform.

With this latest funding round, Solace Health has raised a total of $211 million. The company plans to use the new capital for marketing and hiring, especially in engineering, product, and design roles. Additionally, Solace intends to establish a research team to publish articles in medical journals about the clinical and financial impacts of advocacy services.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.